Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development (KD) invests in companies developing potentially ground-breaking treatments to relieve or cure serious diseases. Karolinska Development has a focused portfolio comprising pharmaceutical and medtech companies with significant potential for value generation. The portfolio companies develop highly differentiated and commercially attractive products that have the potential to deliver compelling clinical and health economic benefits.
In October 2022, KD announced its participation in a seed financing of Henlez, a privately owned Danish company focused on developing therapies for treatment of the chronic dermatological condition hidradenitis suppurativa.
Its current portfolio also includes:
invoX strategic investment
In October 2021, Sino Biopharmaceutical transferred its holding in Karolinska Development (KD) to the wholly-owned subsidiary invoX. invoX further increased its shareholding to 47.67% with Karolinska Development concluding a rights issue in February 2022.Visit Karolinska Development website